Oncology Market Access in India - The commercial potential is high, but many challenges remain
Datamonitor, October 2011, Pages: 70
The Indian oncology market is forecast to grow strongly in the next decade, driven by the rise in cancer incidence and diagnosis, improved access to cancer therapies, better health insurance coverage, and higher pharmaceutical spending, particularly among the growing middle class. But while pharmaceutical companies are keen to establish a strong presence in India, a number of challenges remain
Features and benefits
- Analysis of the current epidemiology and trends within the Indian oncology market
- In-depth analysis of the opportunities and threats for oncology companies in India
- Discussion of key multinational and domestic companies in the Indian cancer market
- An analysis of the key factors for success in India in the context of the overall healthcare industry
Highlights
- A large part of the Indian population lacks access to appropriate cancer care. A number of reasons contribute to this including inadequate healthcare infrastructure, low health insurance coverage, poor education and low cancer awareness.
- While domestic companies dominate the market with branded generics, all major multinational pharmaceutical companies have a presence in India, targeting a small but significant part of the population that can afford the price premium associated with global brands.
- As the Indian economy continues to grow, more people will gain the financial ability to seek cancer treatment, while the growing middle class will drive demand for innovative branded therapies. Plans to increase government expenditure on health and improve access to cancer drugs will also drive the uptake of cancer therapeutics in the future
Your key questions answered
- Appreciate the structure of cancer care delivery in India, as well as the factors that influence the nature and quality of cancer treatment
- Evaluate the opportunities and threats facing multinational companies wishing to establish or expand their presence in the Indian oncology market
- Identify strategies for market penetration and appreciate the key factors for commercial success
Executive Summary
Scope of the analysis
Datamonitor insight into the Indian oncology market
Related reports
Upcoming reports
OVERVIEW
Catalyst
Summary
CANCER EPIDEMIOLOGY IN INDIA
Background of cancer registration in India
Most common cancers
Cancer temporal trends
Cancer mortality rate trends
DRIVERS OF CANCER EPIDEMIOLOGY IN INDIA
Population dynamics
Population in major urban agglomerations of India
Risk factors driving cancer epidemiology in India
Dietary factors
Infectious agents
Environmental and occupational exposures
Physical activity, overweight, and obesity
Limitations of Indian cancer data
MARKET OVERVIEW
Key findings
Structure of cancer care
India has a layered cancer care delivery system
Access to oncology services
There is a lack of certified medical oncologists in India
Access to cancer care is limited for a large part of the Indian population
Low insurance coverage makes cancer care unaffordable for most
The wealthy and middle-class seek high-quality care in the private sector
Cancer treatment
Generic therapies dominate the market in India
Generic versions exist for many small molecule cancer therapies
Despite patent protection, market exclusivity is not guaranteed in the Indian oncology market
Current treatment is based on US and European guidelines
A number of factors compromise the delivery of high-quality, evidence-based cancer care
The drug distribution system
KEY COMPANIES
Key findings
Overview of the Indian oncology market
Most global compannies operate in the Indian oncology market
Multinational corporations
Roche
Novartis
Domestic companies
Dr. Reddy’s
Recent deals and alliances of Natco in oncology
Deals and alliances in the Indian oncology market
Research and development agreements
Agreements in the oncology diagnostics sector
Generics manufacturing and co-marketing agreements
Joint ventures in the Indian oncology market
MARKET ACCESS
Key findings
Strategies for market penetration
Overview of general market entry strategies in India
Launching novel, patented products remains the most viable strategy for growth in oncology
Companies should increase their reach in the small- and mid-sized cities and rural areas
Targeting key cancer indications can help increase the potential patient base
The use of patient assistance programs may enhance brand awareness
SWOT analysis of the Indian oncology market
Strengths
Weaknesses
Opportunities
The government is prioritizing cancer treatment, with plans to improve access to cancer drugs
India is an attractive market in which to perform clinical trials
Threats
Price controls may further impact pharma’s pricing power
The use of compulsory licenses may effectively end market exclusivity for many cancer drugs
Growth of the biosimilars market will minimize commercial attractiveness for foreign developers
Concern over multinational M&A activity has tightened barriers to entry for foreign pharma companies
Domestic companies may invest heavily in R&D, competing for a share of the branded market
Counterfeit drugs are a threat to patients and sales revenues
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Other
APPENDIX
Contributing experts
Report methodology
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
